The purpose of this study was to determine the @entity137 and efficacy of single daily fractionation as compared with twice-a-day radiation therapy in combination with chemotherapy for preoperative locally advanced thoracic @entity418 . A retrospective survey was done of 42 @entity1 undergoing concurrent chemotherapy and radiation for preoperative locally advanced thoracic @entity418 . Twenty-five @entity1 had @entity1487 ( @entity1487 ), 1,000 mg/m2/d by continuous infusion, days 1-5, and days 22-26), @entity900 (100 mg/m2 intravenously, days 2 and 22), and radiation to a total dose of 4,500 to 5,040 cGy in 180 cGy/fraction every day. Seventeen @entity1 received @entity1487 (300 mg/m2/d by continuous infusion, days 1 and 21), @entity900 (20 mg/m2/d for 1 hour, days 1-5 and days 17-20), @entity5713 (1 mg/m2 intravenously, days 1-5 and days 17-21) and accelerated hyperfractionated radiation 150 cGy twice a day to a total dose of 4,500 cGy. Response rate, survival, local regional failure rates, and treatment @entity137 of the two groups were compared. Surgery was aborted in one @entity1 and another @entity1 refused surgery in the single daily-fractionation group. All @entity1 underwent surgery in the twice-daily group. Complete response (CR) was noted in 12 @entity1 (52%) in the single daily-fractionation group as compared with 9 @entity1 (52%) in the twice-daily group. The median and 3-year survival were 20 months and 35%, respectively, in the single daily-fractionation group. Corresponding figures were 18 months and 32%, respectively, in the twice-daily group. For the 2 groups combined, a statistically significant improvement in survival was observed among blacks who achieved a CR (31 months) as compared with the ones with @entity66 (13.5 months). Local and regional failures were 28% and 17%, respectively, for the single daily-fractionation and twice-daily groups. Distant metastases remained significant in both groups and were 36% (single daily-fractionation) and 41% (twice-daily), respectively. Grades III to IV @entity2910 and @entity1503 developed in 36% and 64% of @entity1 of the single daily-fractionation and twice-daily groups, respectively. The incidence of late complications was 16% (single daily-fractionation) and 11.7% (twice-daily). Preoperative chemotherapy and radiation is effective to achieve a high pathologic CR. Both radiation therapy fractionation schedules are comparable in efficacy and @entity137 . Further investigations should be done to assess whether ethnicity may play a role in the prognosis of @entity418 .

Preoperative chemotherapy and radiation for advanced XXXX : comparison between once a day radiation and hyperfractionation, a single-institution experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal carcinoma'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['[5-FU]', '5-FU', '5-fluorouracil']
@entity418 :: (MESH:D004938,Disease) :: ['esophageal carcinoma']
